Witkowska Magdalena, Malicki Mikołaj, Marcinkowska Weronika, Kościelny Kacper, Kowalik Adrianna, Mikulski Damian, Mirocha Grzegorz
Department of Hematology, Medical University of Lodz, Lodz, Poland.
Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland.
Leuk Res Rep. 2025 Jun 17;24:100519. doi: 10.1016/j.lrr.2025.100519. eCollection 2025.
With the introduction of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and radiation combined, the prognosis of Hodgkin lymphoma (HL) has significantly improved, with 5-year overall survival of around 90 %. While the lymphoma has become highly curable, the side effects of ABVD treatment are dire and warrant continuous review. Immune checkpoint inhibitors, including nivolumab, have demonstrated high therapeutic efficacy in relapsed and refractory HL patients. Nevertheless, despite much data, the therapy duration and long-term efficacy question remains unresolved. In this retrospective study, in a cohort of 10 patients, we observed a high complete response (CR) rate, while during long-term observation, 5 patients relapsed, and 3 had autoimmune treatment-related complications.
随着多柔比星、博来霉素、长春碱和达卡巴嗪（ABVD）与放疗联合应用，霍奇金淋巴瘤（HL）的预后有了显著改善，5年总生存率约为90%。虽然淋巴瘤已变得高度可治愈，但ABVD治疗的副作用严重，值得持续评估。包括纳武单抗在内的免疫检查点抑制剂在复发和难治性HL患者中已显示出高治疗疗效。然而，尽管有大量数据，但治疗持续时间和长期疗效问题仍未解决。在这项回顾性研究中，在一组10例患者中，我们观察到高完全缓解（CR）率，而在长期观察期间，5例患者复发，3例出现与自身免疫治疗相关的并发症。
